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Abstract
Background
Huntington’s disease patients have a number of peripheral manifestations suggestive of
metabolic and endocrine abnormalities. We, therefore, investigated a number of metabolic
factors in a 24-hour study of Huntington’s disease gene carriers (premanifest and moderate
stage II/III) and controls.
Methods
Control (n = 15), premanifest (n = 14) and stage II/III (n = 13) participants were studied with
blood sampling over a 24-hour period. A battery of clinical tests including neurological rating
and function scales were performed. Visceral and subcutaneous adipose distribution was
measured using magnetic resonance imaging. We quantified fasting baseline concentra-
tions of glucose, insulin, cholesterol, triglycerides, lipoprotein (a), fatty acids, amino acids,
lactate and osteokines. Leptin and ghrelin were quantified in fasting samples and after a
standardised meal. We assessed glucose, insulin, growth hormone and cortisol concentra-
tions during a prolonged oral glucose tolerance test.
Results
We found no highly significant differences in carbohydrate, protein or lipid metabolismmark-
ers between healthy controls, premanifest and stage II/III Huntington’s disease subjects.
For some markers (osteoprotegerin, tyrosine, lysine, phenylalanine and arginine) there is a
suggestion (p values between 0.02 and 0.05) that levels are higher in patients with
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premanifest HD, but not moderate HD. However, given the large number of statistical tests
performed interpretation of these findings must be cautious.
Conclusions
Contrary to previous studies that showed altered levels of metabolic markers in patients
with Huntington’s disease, our study did not demonstrate convincing evidence of abnormali-
ties in any of the markers examined. Our analyses were restricted to Huntington’s disease
patients not taking neuroleptics, anti-depressants or other medication affecting metabolic
pathways. Even with the modest sample sizes studied, the lack of highly significant results,
despite many being tested, suggests that the majority of these markers do not differ
markedly by disease status.
Introduction
Huntington’s disease (HD) is a devastating hereditary neurodegenerative disorder character-
ised by progressive motor, cognitive and psychiatric impairment [1]. In recent years it has
become clear that HD can be regarded as a systemic disorder affecting many organs and tissues
causing peripheral as well as brain pathology [2]. Both animal and human studies indicate that
some of the peripheral symptoms of HD, including weight loss and alterations in appetite,
could be linked to endocrine and metabolic alterations [3, 4]. These alterations may be reflected
in plasma levels of carbohydrate, lipid or protein metabolites and/or hormones related to
energy metabolism.
Carbohydrate metabolism
Studies of carbohydrate metabolism in patients with HD have generated ambiguous and con-
flicting results. Metabolic profiling of serum samples has shown significant changes in various
monosaccharide levels, particularly glucose, between HD gene carriers and controls [5] and
studies have shown impaired glucose tolerance and increased prevalence of diabetes in HD
patients [6–8]. Insulin sensitivity studies in HD patients have shown both a decrease in insulin
sensitivity and impaired insulin secretion capacity in normoglycemic subjects [9]. However,
other studies in HD patients have reported normal glucose and insulin levels following a glu-
cose tolerance test, as well as normal fasting glucose and insulin [10–15].
Lipid metabolism
HD patients display changes in body fat stores, as indicated by decreased visceral and periph-
eral adiposity [15–17]. In addition, altered fatty acid metabolism and changes in various mark-
ers of fatty acid breakdown have been reported in HD [5, 18]. Dysfunction of the cholesterol
biosynthetic pathway has also been shown in HD [19, 20] and cholesterol precursors and
metabolites have been shown to be reduced in manifest HD patients [21, 22]. However, studies
measuring total cholesterol concentration in plasma have reported both low [23, 24] and nor-
mal levels [21] in HD patients compared to healthy controls.
Protein metabolism
Muscle wasting is a common feature of HD [15–17] and abnormal in vivo skeletal muscle
energy generation has been shown in both symptomatic patients with HD and presymptomatic
AMetabolic Study of HD
PLOSONE | DOI:10.1371/journal.pone.0146480 January 8, 2016 2 / 16
mutation carriers [25–28]. Several studies of amino acid metabolism in patients with HD have
found a decrease in the concentrations of neutral amino acids (especially alanine, valine, leu-
cine and isoleucine) in HD plasma [5, 14, 18, 29–34].
Gastric and adipose hormones
Ghrelin, an orexigenic peptide of gastric origin, and leptin, a peptide hormone secreted by adi-
pose tissue, are two peripherally produced hormones that exert effects on the hypothalamus in
the regulation of body energy homeostasis [35]. Leptin induces weight loss by suppressing food
intake and stimulating metabolic rate, whereas ghrelin stimulates appetite and increases adi-
posity [36, 37]. Studies on leptin in HD patients have reported similar concentrations in HD
patients and controls [38, 39]. Conversely, it has also been reported that patients with HD have
increased ghrelin and decreased leptin concentration in plasma compared with healthy con-
trols [14, 24, 40].
Aim of the study
The aim of this study was to evaluate a number of metabolic variables to assess whether they
are linked to disease state in a cross-sectional study of cohorts of HD gene carriers and controls.
We studied carbohydrate, lipid and protein metabolites as well as hormones related to energy
metabolism in plasma samples from well-characterised cohorts of premanifest and moderate
HD subjects and healthy controls.
Materials and Methods
Study participants
The study was approved by the joint UCL/UCLH ethics committee. Patients were eligible for
enrollment if they were 18 years of age or older, had completed either a predictive test for pre-
manifest subjects, or had a confirmed genotype consistent with HD (CAG repeat40).
Patients committed to undergo a 24-hour inpatient stay for the study and a body magnetic res-
onance imaging (MRI) scan. Controls were recruited principally from the partners, spouses, or
caregivers of the HD group and exclusion criteria were the same as for the HD group.
Subjects were excluded if they had a history of alcohol or drug abuse in the preceding 12
months or if they had received medication in the preceding 6 months that could influence the
hypothalamic-pituitary axis, such as corticosteroid treatment, antipsychotic medication includ-
ing phenothiazine, or antiemetic drugs. Subjects could not have any pre-existent endocrine dis-
eases, such as diabetes, or central nervous system disorder such as head trauma and seizures.
Patients with metallic implants (contraindicated for MRI scan), those experiencing recent
weigh loss or gain, and night shift workers were also excluded.
Clinical protocol
The clinical protocol was described previously [41]. Study subjects were admitted to a private
clinical room and had an intravenous cannula inserted. During the day the subject could walk
freely, watch television, but not fall asleep or snack outside scheduled mealtimes. Scheduled
meal times were: breakfast at 09.00, standardised test meal at 12:00 and dinner at 18:00. At
22:00 they retired to bed for sleep and lights were turned off. Lights were switched on again at
06:00. Hourly blood samples were taken over the 24-hour period using a long line from 14:00
to 13:00 the following day.
Clinical assessment and HD rating scales were performed by a neurologist with expertise in
HD (TTW). Clinical assessment of patients was performed by taking the medical history and
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performing a whole body physical and neurological examination. The Unified Huntington’s
Disease Rating Scale (UHDRS) was used to quantitatively measure HD signs [42–45]. Cogni-
tive function was assessed by Stroop Test Evaluation Colour Naming (STECN), Stroop Test
Evaluation Word Reading (STEWR), Stroop Test Evaluation Interference (STEI), Symbol Digit
Test (SDT) and Verbal Fluency Test (VFT). Problem Behaviours Assessments were also
performed.
Biometric data were obtained including body mass index (BMI), scapular fat thickness
(SFT), waist-to-hip ratio (WHR) and circumference of the abdomen (CA). In addition, partici-
pants underwent a T1-weighted abdominal MRI scan in order to assess the visceral and subcu-
taneous adipose tissue using Hippofat software [46]. Visceral and subcutaneous adipose
deposition was measured because, despite weight loss, enhanced accumulation of body fat in
mid-life has been found in several HD mouse models [47–49].
Collection and processing of human samples
Whole blood samples for lactate and plasma samples for glucose analysis were analysed on the
day of collection: prior to analysis, lactate samples were kept on ice while glucose samples were
kept at room temperature. Blood samples for insulin analysis were collected on ice and centri-
fuged immediately for 5 minutes at 2500 revolutions per minute (RPM) at 4°C, the serum col-
lected, immediately placed on dry ice, and stored at -80°C until analysis. Blood samples for
cortisol, growth hormone, leptin, ghrelin, total cholesterol, high-density lipoprotein (HDL)-
cholesterol, low-density lipoprotein (LDL)-cholesterol and triglyceride analysis were allowed
to clot at room temperature for 30 minutes, then centrifuged and stored as above. Blood sam-
ples for analysis of fatty acids, amino acids, β-hydroxybutyrate, lipoprotein (a), apolipoproteins
and osteokines were immediately placed on ice, and centrifuged within 5 minutes of sampling,
at 4°C at 2500 RPM for 5 minutes. Plasma was collected, immediately placed on dry ice and
stored at -80°C until analysis. Leptin and ghrelin levels were assessed on two occasions: at
06:00 and 13:00, one hour after a standardised, 550 kcal meal comprising 30% lipids, 50% car-
bohydrates and 20% proteins [50, 51].
A 3-hour Oral Glucose Tolerance Test (GTT) was performed from 06:00 to 09:00 with
blood samples taken just prior to and at 30 minutes intervals after ingestion of an oral glucose
load of 75 grams. These samples were used for glucose, insulin, cortisol and growth hormone
analysis. The homeostasis model assessment of beta-cell function and insulin resistance
(iHOMA2) was used in default mode to calculate insulin secretion and sensitivity [52]. For
each patient, any perturbation in glucose & insulin homeostasis was quantified using the
Observed Variability and Lability (OVAL) model [53]. Diabetes was defined as fasting plasma
glucose>7 mmol/L and/or 2 hour sample>11.2. Impaired glucose tolerance was defined as
fasting plasma glucose<7 mmol/L and 2 hour sample between 7.8 and 11.1 mmol/L and
impaired fasting glycaemia as fasting blood glucose between 6.1 mmol/L and 6.9 mmol/L and 2
hour sample<7.8 mmol/L.
Sample analysis
Plasma glucose was assayed on the Roche Modular P Analyser using the glucose oxidase
method, whereas whole blood lactate was measured on the Siemens Blood Gas Analyser.
Serum insulin was analysed by a microparticle immunoassay run on an Abbott AxSYM Analy-
ser. Serum cortisol concentrations were determined by electrochemiluminescent immunoassay
on a Roche Modular E170 Autoanalyser. Serum growth hormone was quantified using a
chemiluminescent immunoassay on a Siemens Immulite Analyser. Serum leptin was measured
by an enzyme-linked immunosorbent assay (R&D Systems Europe, Abingdon, UK), while
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serum active ghrelin was measured by radioimmunoassay (Millipore, Billerica, MA, USA). The
plasma amino acid profile was determined by reversed-phase partition high performance liquid
chromatography (HPLC) and by ion exchange chromatography as previously described [14].
Osteokines and the bone-specific isoform of alkaline phosphatase were quantified using the
Human Bone Panel I and II assays as per the manufacturer’s protocol (Meso Scale Discovery,
Rockville, MD, US). Apolipoproteins and lipoprotein (a) were measured by immunonephelo-
metry on a Siemens BN2 analyser. Total cholesterol, HDL and triglycerides were measured
using enzymatic-spectrophotometric assays on a Roche Modular P Analyser. LDL concentra-
tion was calculated from the Total cholesterol, HDL and Triglyceride results using the Friede-
wald equation [54]. Serum leptin and ghrelin, and plasma amino acids and osteokines were
measured in duplicate and readings averaged. All other variables were single measurements.
Statistical Analysis
Inter-group differences were assessed using linear regression models with group, age and gender
as predictor variables. Where residuals were not normally distributed, variables were logarithmi-
cally transformed and the analysis repeated. For all regression models joint F-tests were used to
compare adjusted group means. A chi-square test was used to compare proportions of subjects
with and without impaired glucose tolerance. The significance level was set at p<0.05. Statistical
analyses were performed using SPSS for Windows (release 16.0, SPSS, Inc., Chicago, IL) and
using Stata (StataCorp Stata Statistical Software: Release 13. College Station, TX: StataCorp LP).
Results
Fifteen control subjects, 14 premanifest HD gene carriers, and 13 moderate (stage II/III) HD
patients were enrolled into the study. Study participant characteristics are summarised in Table 1.
Carbohydrate metabolism
Glucose tolerance test. We performed a glucose tolerance test with blood sampling every
30 minutes over 3 hours and quantified glucose, insulin, cortisol and GH in these samples. No
significant difference between control, premanifest and stage II/III HD subjects was found in
baseline glucose, insulin, GH and cortisol concentrations, nor during the glucose tolerance test
(Fig 1). Fig 1A and 1B suggests there may be a blunted insulin and GH response in stage II/III
HD compared to healthy controls but this did not reach statistical significance. We used a chi-
square test to compare proportions of subjects with and without impaired glucose tolerance.
The proportion of subjects with glucose intolerance did not differ between controls, premani-
fest HD and stage II/III HD subjects (χ2 = 0.039, P = 0.981).
Table 2 shows the mean and SD of homeostatic model assessment (HOMA)-S and HOMA-
β which are measures of insulin secretion and beta cell function respectively, as well as OVAL,
a measure of fasting glucose-insulin homeostasis, in controls, premanifest and stage II/III HD
patients. After adjustment for age and gender there was no significant difference in HOMA-S,
HOMA-β or OVAL between the three groups. Higher HOMA-S and OVAL homeostasis was
observed in premanifest HD subjects compared to control and stage II/III HD subjects and
higher HOMA-β was observed in stage II/III HD compared to controls and premanifest HD
subjects, however none reached statistical significance (Table 2).
Bone turnover markers
We investigated markers of bone turnover by measuring proteins released during bone forma-
tion and degradation products produced during bone resorption [55]. After adjustment for age
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and gender we did not observe a significant difference in bone formation markers bone alkaline
phosphatase, oesteocalcin and osteonectin, nor in the inhibitor of bone formation, sclerostin,
between control and HD subjects (Table 2). Between group differences in the bone resorption
marker osteoprotegerin were statistically significant (p = 0.0497), but given the borderline
nature of the p-value, the number of statistical tests performed (and corresponding increased
risk of false positive findings), and the fact that the statistical significance was driven by
adjusted levels in the pre-manifest being higher than those in the other two groups which were
similar to one another, we are inclined to regard this as a chance finding.
Lipid metabolism
In the current study we measured levels of total cholesterol (TC), low-density lipoprotein
(LDL), high-density lipoprotein (HDL), triglycerides (TGS), apolipoprotein A1 (ApoA1), apo-
lipoprotein B (ApoB), lipoprotein (a), fatty acids and B-hydroxybutyrate (or sodium
3-hydroxybutyrate). There was no significant difference in concentrations of any of the above
variables between the three groups after adjustment for age and gender (Table 2).
T1 weighted abdominal MRI was used to quantitate visceral and subcutaneous adipose tis-
sue using Hippofat software that automatically quantifies adipose tissue areas without user
inputs [46, 56]. Adipose tissue characterisation in the three groups was similar (Table 1).
Protein metabolism
Amino acids. We investigated fasting levels of amino acids, including branched chain
amino acids (BCAAs, i.e. valine, leucine and isoleucine) in plasma samples using reversed-
phase HPLC. After adjustment for age and gender statistically significant between group
Table 1. Demographic and clinical characteristics of control and HD subjects.
Stage Controls Premanifest HD Stage II/III HD
Number of subjects 15 14 13
Mean age (range) 52 (29–69) 45 (31–58) 55 (42–70)
Female:Male 6:9 9:5 5:8
Mean CAG (range) - 42 (40–47) 44 (42–47)
Mean burden score (range) - 301 (207–434) 435 (273–702)
Mean UHDRS Total Functional Capacity - 13 (12–13) 8 (5–12)
Mean UHDRS Motor ScoreMean - 2 (0–11) 38 (10–65)
BMI ± SD 26.0 ± 4.3 28.9 ± 4.7 25.7 ± 3.5
Mean scapular fat thickness ± SD (mm) 15.5 ± 7.2 22.2 ± 6.3** 17.5 ± 7.3*
Mean waist to hip ratio ± SD 0.87 ± 0.09 0.89 ± 0.08** 0.88 ± 0.06*
Mean abdominal circumference ± SD (cm) 92.1 ± 14.3 102.2 ± 14.0*** 94.4 ± 11.0**
Subcutaneous adipose tissue ± SD (cm2) 158.4 ± 53.7* 265.3 ± 148.4**** 176.7 ± 87.0
Visceral adipose tissue ± SD (cm2) 118.5 ± 92.8** 95.5 ± 59.7**** 117.5 ± 56.9
Total fat ± SD (cm2) 281.8 ± 115.7** 360.8 ± 154.9**** 294.2 ± 112.8
Body area ± SD (cm2) 605.6 ± 197.5* 690.8 ± 156.0**** 620.2 ± 115.7
VAT/SAT ratio ± SD (cm2) (%) 79.6 ± 77.3** 51.2 ± 57.8**** 77.5 ± 54.6
SAT % 44.2 ± 7.0** 50.5 ± 13.8**** 46.3 ± 12.6
* One missing value
** Two missing values
*** Three missing values
**** Four missing values.
doi:10.1371/journal.pone.0146480.t001
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Fig 1. Mean blood glucose levels at different time points during a glucose tolerance test in controls, premanifest andmoderate HD patients and
the corresponding mean insulin (A), growth hormone (B) and cortisol (C) concentrations.
doi:10.1371/journal.pone.0146480.g001
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differences were found in phenylalanine, lysine and arginine concentrations (all three p-values
between 0.02 and 0.05), although finding three such results is consistent with random chance
given the number of variables investigated. In addition, in each case the statistical significance
is driven by the fact that adjusted mean levels in the premanifest group were markedly higher
than those in the stage II/III group and the controls, with mean levels in these two groups
being similar, suggesting that this is not a biologically plausible finding. We did not find any
significant between group differences in any of the other amino acids analysed (Table 3). We
also quantified amino acid concentration using ion exchange chromatography as previously
described [14]. After adjustment for age and gender only one variable (Tyrosine) differed sig-
nificantly between groups, the result being only just statistically significant (p = 0.04) and again
with adjusted levels highest in the premanifest group (Table 3).
Table 2. Fasting levels of metabolic markers in control, premanifest and stage II/III HD cohorts. Data are presented as Mean ±SD for normally distrib-
uted data and as median [minimum—maximum] for skewed data.
Control (n = 15) Premanifest HD (n = 14) Stage II/III HD (n = 13) p
Carbohydrate metabolism
GTT–OVAL 317.97 ± 181.26 317.03 ± 139.00 440.78 ± 210.02 0.30
GTT–HOMA-S 282.14 ± 126.40 301.75 ± 93.71 378.47 ± 136.65 0.16
GTT–HOMA-β 45.20 ± 13.49 51.65 ± 21.67 43.35 ± 13.13 0.82
Lactate (mmol/l) 1.17 ± 0.26 1.30 ± 0.29 1.17 ± 0.41 0.39˄
Bone markers:
Alkaline phosphatase, ng/ml 31.89 ± 8.28 36.12 ± 11.90 37.44 ± 10.83 0.38
Osteocalcin, ng/ml 42.64 ± 23.86 30.27 ± 11.58 39.88 ± 13.69 0.24
Osteonectin, ng/ml 121.6 [34.0–414.6] 167.5 [78.0–811.6] 122.2 [61.0–1340.2] 0.23*
Osteoprotegerin, ng/ml 0.20 ± 0.04 0.22 ± 0.04 0.21 ± 0.04 0.05
Sclerostin, ng/ml 0.25 ± 0.12 0.27 ± 0.12 0.26 ± 0.11 0.90
Lipid metabolism
Total cholesterol (mmol/l) 4.69 ± 0.97 4.75 ± 1.03 4.57 ± 1.15 0.99
LDL cholesterol (mmol/l) 2.73 ± 0.83 3.01 ± 0.79 2.77 ± 1.04 0.86
HDL cholesterol (mmol/l) 1.46 ± 0.46 1.28 ± 0.39 1.35 ± 0.49 0.41
Triglycerides (mmol/l) 1.11 ± 0.45 1.18 ± 0.47 1.02 ± 0.47 0.41
Lipoprotein (a) (g/L) 0.17 ± 0.13 0.33 ± 0.28 0.20 ± 0.21 0.28
Apolipoprotein A1 (g/L) 1.40 ± 0.25 1.43 ± 0.31 1.35 ± 0.25 0.94
Apolipoprotein B (g/L) 0.77 ± 0.20 0.89 ± 0.21 0.82 ± 0.22 0.40
Fatty acids (mmol/l) 0.48 ± 0.21 0.41 ± 0.16 0.44 ± 0.20 0.55˅
B-hydroxybutyrate (mmol/l) 0.13 ± 0.09 0.07 ± 0.04 0.09 ± 0.06 0.09˄
Hormones
Leptin (ng/ml), fasting 9.91 [4.38–27.44] 28.69 [2.39–116.22] 9.32 [2.22–52.02] 0.19*
Leptin (ng/ml), postprandial 8.70 [3.26–28.09] 28.29 [2.00–72.91] 8.48 [3.15–42.24] 0.19*
Ghrelin (pg/ml), fasting 57.90 [30.67–32.37] 77.07 [48.29–173.69] 58.85 [32.19–122.66] 0.05*
Ghrelin (pg/ml), postprandial 56.61 [27.46–51.73] 50.78 [39.97–133.87] 58.91 [30.87–131.18] 0.67*$
Unless otherwise indicated p-values are from linear regression models, comparing group means after adjustment for gender and age.
*p-value from linear regression of log transformed values, comparing group means after adjustment for gender and age.
˄Control (n = 13); Premanifest HD (n = 13); Stage II/III HD (n = 12)
˅Control (n = 14); Premanifest HD (n = 14); Stage II/III HD (n = 12)
$Control (n = 14); Premanifest HD (n = 14); Stage II/III HD (n = 13)
doi:10.1371/journal.pone.0146480.t002
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Gastric and adipose hormones
We investigated fasting and postprandial serum levels of leptin and ghrelin. Fasting (06:00)
ghrelin levels were higher in premanifest HD patients, but not in stage II/III HD patients, a
borderline significant result (p = 0.051 for comparison between 3 groups, adjusted for age and
gender). As with the amino acid data, this finding is unlikely have a biological underpinning
and is consistent with chance. There was no significant difference in fasting (06:00) or post-
prandial (13:00) leptin or in postprandial (13:00) ghrelin levels between controls, premanifest
and stage II/III HD subjects (Table 2).
Discussion
Peripheral manifestations of Huntington’s disease such as weight loss and muscle wasting are
thought to be linked to altered metabolism [2]. In this study we investigated metabolic alter-
ations through evaluating circulating metabolic factors and functional tests. In contrast to
many previous studies, we found little evidence to support alterations in metabolic markers
with respect to disease progression. The differences in the findings between our study and
Table 3. Protein metabolism. Levels of amino acids (μmol/L) in control, premanifest and stage II/III HD cohorts as determined by ion exchange chromatog-
raphy and reversed-phase HPLC. Data are presented as Mean (SD).
Amino acid Ion exchange chromatography Reversed-phase HPLC
Control
(n = 12)
Premanifest HD
(n = 11)
Stage II/III HD
(n = 12)
p Control
(n = 14)
Premanifest HD
(n = 14)
Stage II/III HD
(n = 12)
p
Taurine 137.3 (46.6) 127.9 (41.3) 141.5 (37.7) 0.91 70.3 (27.0) 78.4 (22.2) 65.0 (17.9) 0.16
Aspartic Acid 5.4 (3.2) 5.7 (3.7) 5.6 (1.5) 0.97 4.0 (2.2) 5.2 (2.8) 3.3 (1.2) 0.56
Threonine 144.8 (34.1) 146.7 (31.5) 141.6 (38.8) 0.53 139.4 (35.2) 123.1 (42.1) 134.7 (24.8) 0.59
Serine 127.0 (26.9) 127.8 (27.5) 126.8 (25.5) 0.99 118.7 (27.3) 125.7 (34.2) 115.0 (20.0) 0.68
Asparagine 62.8 (11.6) 64.1 (19.7) 59.5 (10.0) 0.57 57.0 (14.0) 57.8 (12.0) 50.0 (6.3) 0.19
Glutamic Acid 58.5 (30.0) 50.9 (19.8) 54.4 (24.8) 0.63 93.1 (81.2) 96.2 (62.4) 79.1 (36.9) 0.27
Glutamine 620.2 (97.4) 580.0 (87.1) 628.1 (71.1) 0.98 622.1 (146.0) 576.0 (86.0) 630.2 (70.2) 0.72
Proline 210.6 (48.3) 189.8 (62.8) 191.8 (63.3) 0.50 168.9 (54.7) 164.4 (37.7) 154.1 (44.7) 0.27
Glycine 268.8 (115.7) 282.5 (126.2) 275.6 (121.0) 0.99 246.6 (114.7) 245.9 (106.1) 243.7 (85.4) 0.99
Alanine 383.7 (151.0) 464.4 (126.2) 421.5 (100.6) 0.25 326.7 (123.7) 382.7 (55.3) 347.7 (84.9) 0.22
2-aminobutyric
acid
31.5 (10.4) 28.7 (5.3) 30.3 (8.2) 0.63
Citrulline 45.8 (13.2) 47.2 (17.2) 52.7 (17.1) 0.56
Valine 259.9 (52.9) 278.1 (60.3) 260.7 (47.8) 0.06 231.2 (51.4) 241.3 (41.8) 233.8 (36.4) 0.17
Cysteine 109.1 (29.1) 95.7 (19.6) 107.3 (29.7) 0.91
Methionine 24.3 (3.9) 25.5 (4.6) 25.3 (4.8) 0.24 24.4 (7.7) 26.2 (4.7) 24.0 (4.0) 0.19
Isoleucine 77.5 (21.2) 74.3 (18.0) 74.8 (18.0) 0.45 68.2 (20.5) 66.7 (12.5) 64.6 (13.8) 0.28
Leucine 134.8 (30.4) 140.7 (32.1) 139.7 (28.7) 0.11 127.6 (31.4) 134.3 (25.1) 129.2 (26.5) 0.09
Tyrosine 63.9 (15.8) 72.4 (11.3) 70.4 (8.9) 0.04 55.9 (16.4) 63.4 (12.1) 60.6 (9.4) 0.14
Phenylalanine 56.8 (10.0) 61.5 (5.9) 62.3 (10.7) 0.07 54.7 (11.0) 61.4 (7.0) 57.9 (8.4) 0.02
Ornithine 63.6 (13.7) 59.9 (20.0) 71.5 (23.7) 0.69 52.5 (13.9) 52.9 (16.6) 60.8 (15.0) 0.43
Histidine 76.9 (10.6) 78.5 (7.8) 82.3 (9.6) 0.47 83.4 (16.2) 90.6 (9.8) 84.8 (10.4) 0.25
Lysine 178.1 (34.8) 188.3 (36.8) 191.3 (31.6) 0.41 184.7 (40.8) 209.4 (29.1) 186.8 (33.1) 0.02
Arginine 85.9 (16.3) 93.1 (18.7) 98.1 (21.0) 0.14 87.3 (14.9) 106.8 (28.1) 96.8 (11.3) 0.05
Tryptophan 55.5 (12.6) 60.7 (9.6) 52.7 (9.2) 0.20
P-values are from linear regression models, comparing group means after adjustment for gender and age.
doi:10.1371/journal.pone.0146480.t003
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previously published reports could be due to several reasons including cohort differences, sam-
ple handling and storage and differences in methodology. For instance, in our cohort we
excluded patients on medication that could affect the hypothalamic-pituitary axis, and those
who had experienced recent weight changes, which may have excluded some of the most
severely affected HD patients. We also studied patients in a standardised way to control for
exercise, diet and sleep.
Glucose metabolism
Several studies suggest a high prevalence of glucose intolerance and diabetes mellitus in
patients with HD [7, 8, 16, 17]. In addition, HDmouse models display pancreatic islet cell atro-
phy and intranuclear inclusions [57, 58]. Insulin sensitivity studies in HD patients show both a
decrease in insulin sensitivity and impaired insulin secretion capacity in normoglycemic sub-
jects [9]. Conversely, other studies in HD patients reported normal glucose and insulin levels
following a glucose tolerance test, as well as normal fasting glucose and insulin [10–15]. Failure
of GH suppression after glucose load [59], as well as an early GH and cortisol rise after an insu-
lin tolerance test have been reported in HD [12, 60]. Adrenal cortical hypertrophy and
increased cortisol levels were found in R6/2 mice and it was suggested that this resulted in
reduced bone mineral density, skeletal muscle atrophy and insulin resistance [47].
In our study there was no significant difference in the insulin, growth hormone curve or
cortisol secretion throughout the oral glucose tolerance test. There was no increased incidence
of altered glucose homeostasis in patients with moderate and premanifest HD. The fact that
patients with diagnosed diabetes were excluded in our study would not explain this lack of dif-
ference in glucose tolerance in patients without overt diabetes.
Peripheral hormones: Leptin and Ghrelin
White adipose tissue, a peripheral endocrine organ, releases adipokines such as leptin and has
a key role in energy metabolism and weight regulation. Leptin controls satiety, energy expendi-
ture and neuroendocrine function through hypothalamic pathways [61, 62]. Leptin affects lipid
metabolism, stimulates fatty acid oxidation and inhibits hepatic triglyceride accumulation [36].
Ghrelin is a gut peptide and is a natural ligand to growth hormone secretagogue receptor
[34]. Produced by cells in the oxyntic glands of the stomach, it exerts a counter regulatory effect
on leptin and it increases adiposity as it normally stimulates food intake and inhibits energy
expenditure [36].
It has been suggested that HD patients are in a hypercatabolic state with negative energy
balance [5, 63]. Endocrine links between the stomach, adipocytes and the brain that regulate
energy intake and growth hormone release have been implicated in these processes. Popovic
and colleagues (2004) found increased levels of ghrelin and decreased leptin levels in plasma
from HD patients in non-fasting state, suggestive of negative energy balance [40]. Both ghrelin
and leptin target hypothalamic neurons in the arcuate nucleus, ventromedial and lateral hypo-
thalamus that express high levels of leptin and ghrelin receptors. The selective neuronal loss in
lateral tuberal nucleus of hypothalamus may play a role in weight loss in early HD [4]. This rise
in ghrelin levels and compensatory decrease in leptin levels may help to preserve body weight
and maintain energy homeostasis. Our study is the first to look at fasting and postprandial lep-
tin and ghrelin levels. Contrary to findings in other studies [50, 51, 64], our results did not
show altered leptin or ghrelin levels, except for a borderline significant different in fasting ghre-
lin levels, with higher levels in premanifest (but not stage II/III) HD patients, which we believe
is consistent with chance in view of the large number of analyses performed. It is possible that
more convincing results would be obtained with a higher number of subjects. In keeping with
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these negative results, MRI of abdominal fat tissue did not show significantly altered adipose
tissue depots in human subjects, in contrast to data from HDmouse studies [57]. Again, it
might be that a larger subject cohort is needed, as the MRI data suggest that there might be a
tendency towards altered proportion of subcutaneous versus in visceral fat in premanifest HD.
Lipids
Lipids are vital to the health of the central nervous system, and research has revealed lipid dys-
regulation in HD [65]. This dysregulation has been linked to specific actions of mutant hun-
tingtin on sterol regulatory element binding proteins, resulting in lower cholesterol levels in
affected areas of the brain with evidence that this depletion is pathologic [66]. Studies on lipid
metabolism have reported altered cholesterol and fatty acid metabolism in HD [66]. A meta-
bolic study has demonstrated increases in various markers of fatty acid breakdown, including
glycerol and malonate in HD gene carriers compared to controls [5]. High fasting concentra-
tions of non-esterified fatty acids in HD patients have also been reported [18]. Dysfunction of
the cholesterol biosynthetic pathway has been shown in peripheral fibroblasts and neurons of
manifest HD patients [19, 20] and cholesterol precursors lanosterol and lathosterol, brain-
derived cholesterol metabolite 24S-hydroxycholesterol, and bile acid precursor 27-hydroxy-
cholesterol, were found to be significantly reduced in manifest HD patients [21, 22]. In our
study, we did not observe difference in fasting serum cholesterol levels, however, we did not
quantify levels of cholesterol metabolites.
Proteins
Muscle wasting is a feature of manifest and pre-symptomatic HD. It is thought that the muscle
wasting may be partly a result of impaired mitochondrial function and a local biochemical
defect in HD muscles [67]. Amino acids are the building block of muscle and alterations in
neutral amino acid metabolism in HD patients have been implicated for many years [18, 31].
The most consistent finding appears to be correlation between branched chain amino acid lev-
els (particularly alanine, valine, leucine, isoleucine), weight loss, disease progression and abnor-
mal triplet repeat expansion [5, 14, 18, 29–34]. In addition, considerable systemic alterations in
the kinetics of the kynurenine pathway (a major route accounting for the metabolism of over
90% of the non-protein tryptophan in most tissues) have been reported in patients with HD
[68]. Free plasma tryptophan levels were markedly reduced in HD subjects [18]. It was sug-
gested that this represents dysregulation of energy expenditure and altered mitochondrial elec-
tron transport activity [5]. However, in our study there was no support for amino acid
alteration in HD. Significant findings were found by HPLC for phenylalanine, lysine and argi-
nine, but these would be consistent which chance based on the number of analyses performed
in the study. The same is true for the tyrosine result using ion exchange chromatography and is
supported by the fact that this result is different from the HPLC data. One difference between
our study population and the population previously analysed [14] is that neither our premani-
fest individuals nor our HD patients had a lower BMI compared to controls. Instead, the BMI
of HD gene carriers were higher, particularly in premanifest individuals.
Bone turnover markers
The morphogenesis and remodelling of bone requires the synthesis of bone matrix by osteo-
blasts and its coordinated resorption by osteoclasts. Osteoprotegerin, is a key factor inhibiting
the differentiation and activation of osteoclasts, and is, therefore, essential for bone resorption
[69], whereas osteopontin is an important factor in bone remodelling [70]. Bone cells produce
endocrine hormones that regulate glucose homeostasis [71] and osteocalcin, a bone-specific
AMetabolic Study of HD
PLOSONE | DOI:10.1371/journal.pone.0146480 January 8, 2016 11 / 16
protein, was shown to regulate glucose metabolism in mice [72]. Reduced bone mineral density
has been suggested to be an early feature of HD [73], suggesting that HD patients exhibit osteo-
porosis, probably as a direct effect of illness, due to the effect of mutant huntingtin on osteo-
clasts or osteoblasts in bone tissue or from immobility due to the disease. Bone turnover
markers like osteocalcin, osteopontin and osteoprotegerin were measured in fasted state and
compared to controls, pre-manifest and manifest HD patients. We did not show convincing
evidence of abnormalities in the bone turnover markers measured, which is in keeping with
findings we reported in a different cohort [74]. These data suggest that bone turnover markers
are not useful as markers of bone turnover disturbances in HD.
Limitations of this study
This study compared controls with premanifest and moderate HD patients in a standardised
sampling period of 24 hours. Patients on neuroleptic and other medications, which are known
to affect metabolic pathways, were excluded from this study, a design factor not included in
many previous cohort studies. However, this does mean that patients who may have been more
severely affected were excluded. Whilst we were unable to closely match premanifest and con-
trol group gender and age, we believe this is unlikely to alter our findings. Also, the premanifest
subjects included in the study had a higher BMI compared to controls. It is possible that,
because of high BMI, some of the metabolic dysregulation or compensatory mechanisms that
take place due to the huntingtin mutation may be hidden. However, this would not explain
lack of confirmation of metabolic changes in our stage II/III HD cohort. Another limitation of
the study was the relatively small size of cohorts (13–15 subjects in each). This restricted the
power to identify small to moderate effect sizes in variables. However, the careful controlling of
medication, feeding and timing of sampling in this study meant that the groups were more eas-
ily comparable.
Conclusion
We performed an extensive study focusing on metabolic factors including lipid and bone
markers, glucose homeostasis, peripheral hormones affecting energy homeostasis and amino
acids and their association with Huntington’s disease. In contrast to many previous studies,
our results are consistent with no material differences between HD subjects and control, with
just five statistically significant results (osteoprotegerin, tyrosine, phenylalanine, lysine and
arginine levels), which are most likely to represent chance findings. The predominantly nega-
tive results suggest that the majority of these markers probably do not differ markedly by HD
disease status, however a larger sample size is needed for more definitive evidence of smaller
effects.
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